Clinical Trial Update: DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

View source ↗

Summary

This clinical trial update describes a study using DNA sequencing to monitor minimal residual disease in aggressive B-cell non-Hodgkin lymphoma to predict relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: B-cell Non-Hodgkin Lymphoma, Aggressive | Status: ACTIVE_NOT_RECRUITING